Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ICCC Stock Forecast 2025-2026
$6.12
Current Price
$57.17M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ICCC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
ICCC Price Momentum
-4.5%
1 Week Change
+11.7%
1 Month Change
+44.0%
1 Year Change
+18.8%
Year-to-Date Change
-12.7%
From 52W High of $7.01
+83.2%
From 52W Low of $3.34
📊 TOP ANALYST CALLS
Did ICCC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ImmuCell is one of their latest high-conviction picks.
Latest ICCC Stock Price Targets & Analyst Predictions
ICCC has shown a year-to-date change of 18.8% and a 1-year change of 44.0%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ICCC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICCC Analyst Ratings
0
Buy
0
Hold
0
Sell
ICCC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $6.12
Latest ICCC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICCC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | Nathan Weinstein | Buy | Initiates | $14.00 |
ImmuCell Corporation (ICCC) Competitors
The following stocks are similar to ImmuCell based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ImmuCell Corporation (ICCC) Financial Data
ImmuCell Corporation has a market capitalization of $57.17M with a P/E ratio of 0.0x. The company generates $27.30M in trailing twelve-month revenue with a -1.0% profit margin.
Revenue growth is +11.2% quarter-over-quarter, while maintaining an operating margin of +13.9% and return on equity of -1.0%.
Valuation Metrics
Market Cap
$57.17M
Enterprise Value
$67.23M
P/E Ratio
0.0x
PEG Ratio
-57.5x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
+11.2%
Gross Margin
+41.6%
Operating Margin
+13.9%
Net Margin
-1.0%
EPS Growth
+11.2%
Financial Health
Cash/Price Ratio
+8.3%
Current Ratio
4.1x
Debt/Equity
50.6x
ROE
-1.0%
ROA
+0.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ImmuCell Corporation (ICCC) Business Model
About ImmuCell Corporation
What They Do
Develops biotechnology products for animal health.
Business Model
The company generates revenue through the development, manufacture, and sale of innovative products that enhance animal health and productivity, primarily targeting the dairy and beef industries. Its flagship product, First Defense, addresses critical health issues in livestock by providing alternatives to traditional antibiotics, leading to improved outcomes for farmers and livestock alike.
Additional Information
ImmuCell is positioned within the biotechnology and agricultural markets in the United States, focusing on sustainable farming practices. By promoting healthier livestock and reducing antibiotic dependency, the company aligns with global trends in food safety and agricultural sustainability.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
67
CEO
Mr. Michael F. Brigham
Country
United States
IPO Year
1995
Website
immucell.comImmuCell Corporation (ICCC) Latest News & Analysis
Latest News
Quick Summary
ImmuCell Corporation will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, at 9:30 AM ET, as noted in its April 24 SEC Proxy Statement.
Why It Matters
The announcement of a virtual annual meeting may indicate increased accessibility for shareholders, potentially boosting participation and engagement, which can influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ICCC reports record Q1 sales with returning earnings and expanded margins year-over-year, driven by increased demand for First Defense and resolution of production issues.
Why It Matters
Record Q1 sales and improved margins indicate strong company performance and recovery from previous production issues, boosting investor confidence in future growth potential.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ImmuCell Corporation (NASDAQ: ICCC) will hold a Q1 2025 earnings conference call on May 15, 2025, at 9:00 AM ET to discuss audited financial results for the quarter ended March 31, 2025.
Why It Matters
The upcoming earnings call for ImmuCell Corporation will provide key insights into its financial performance, which can influence stock prices and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ImmuCell Corporation (Nasdaq: ICCC) will release its Q1 2025 unaudited financial results on May 14, 2025, after market close, followed by a conference call on May 15 at 9:00 AM ET.
Why It Matters
ImmuCell's upcoming financial results and conference call may impact stock valuation, providing insights into performance and future prospects in the animal health market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ImmuCell Corporation (Nasdaq: ICCC) reported its unaudited financial results for Q1 2025, focusing on products for dairy and beef cattle health. Further details on financial performance are forthcoming.
Why It Matters
ImmuCell's quarterly financial results can signal growth or challenges in its operations, impacting stock performance and investor sentiment in the animal health sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited sales results for Q1 2025, focusing on products for dairy and beef cattle health and productivity.
Why It Matters
Preliminary sales results from ImmuCell may indicate growth trends, impacting stock performance and investor sentiment in the animal health sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ICCC Stock
What is ImmuCell Corporation's (ICCC) stock forecast for 2025?
Analyst forecasts for ImmuCell Corporation (ICCC) are not currently available. The stock is trading at $6.12.
Is ICCC stock a good investment in 2025?
Analyst ratings for ICCC are not currently available. The stock is currently trading at $6.12. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICCC stock?
Price predictions from Wall Street analysts for ICCC are not currently available. The stock is trading at $6.12.
What is ImmuCell Corporation's business model?
The company generates revenue through the development, manufacture, and sale of innovative products that enhance animal health and productivity, primarily targeting the dairy and beef industries. Its flagship product, First Defense, addresses critical health issues in livestock by providing alternatives to traditional antibiotics, leading to improved outcomes for farmers and livestock alike.
What is the highest forecasted price for ICCC ImmuCell Corporation?
Price targets from Wall Street analysts for ICCC are not currently available. The stock is trading at $6.12.
What is the lowest forecasted price for ICCC ImmuCell Corporation?
Price targets from Wall Street analysts for ICCC are not currently available. The stock is trading at $6.12.
What is the overall ICCC consensus from analysts for ImmuCell Corporation?
Analyst ratings for ICCC are not currently available. The stock is trading at $6.12.
How accurate are ICCC stock price projections?
Stock price projections, including those for ImmuCell Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 10:43 PM UTC